PTPRC and cancer: The CTC-iChip is capable of isolating cells in a tumor antigen-dependent (positive selection) or tumor antigen-independent (negative selection by depletion of WBCs tagged with magnetic bead-conjugated CD45, CD16, and CD66b antibodies) mode; therefore, it is suitable for sorting CTCs of various cancers.